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While a regenerative response is limited in the mammalian adult heart, it has been recently 
shown that the neonatal mammalian heart possesses a marked but transient capacity for 
regeneration after cardiac injury, including myocardial infarction. These findings evidence 
that the mammalian heart still retains a regenerative capacity and highlights the concept 
that the expression of distinct molecular switches (that activate or inhibit cellular mecha-
nisms regulating tissue development and regeneration) vary during different stages of life, 
indicating that cardiac regeneration is an age-dependent process. Thus, understanding 
the mechanisms underpinning regeneration in the neonatal-infarcted heart is crucial to 
develop new treatments aimed at improving cardiovascular regeneration in the adult. 
The present review summarizes the current knowledge on the pathways and factors 
that are known to determine cardiac regeneration in the neonatal-infarcted heart. In 
particular, we will focus on the effects of microRNA manipulation in regulating cardio-
myocyte proliferation and regeneration, as well as on the role of the Hippo signaling 
pathway and Meis1 in the regenerative response of the neonatal-infarcted heart. We will 
also briefly comment on the role of macrophages in scar formation of the adult-infarcted 
heart or their contribution for scar-free regeneration of the neonatal mouse heart after 
myocardial infarction. Although additional research is needed in order to identify other 
factors that regulate cardiovascular regeneration, these pathways represent potential 
therapeutic targets for rejuvenation of aging hearts and for improving regeneration of the 
adult-infarcted heart.
Keywords: cardiac regeneration, mechanisms, therapeutic, targets, aging
Cardiac remodeling and subsequent heart failure (HF) remain critical issues after myocardial 
infarction (MI). Following MI, the adult mammalian myocardium undergoes a complex remod-
eling process initiated by the death of billions of cells within the ischemic region (1). Those are 
mostly cardiomyocytes, endothelial cells, and fibroblasts. The adult mammalian-infarcted heart fails 
to regenerate the lost tissue. Instead, damaged myocardium is replaced by fibrotic tissue, leading 
to altered contractile function and eventually HF (2–4). The World Health Organization and the 
European Cardiovascular Disease Statistics indicate that cardiovascular disease causes over 4 million 
deaths in Europe each year, and more than 40% of these deaths are attributable to MI. Due to the 
considerable improvement in reperfusion techniques the survival rate of patients following MI has 
been dramatically improved (5, 6). However, HF is a frequent complication of MI and remains a 
major cause of morbidity and mortality worldwide (7). Indeed, within 5 years of first MI, 16% of 
men and 22% of women over 45 years of age will develop HF, and the incidence and prevalence of 
HF significantly increases in the elderly population (8, 9). With increasing survival post-MI and an 
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aging population, the prevalence of HF is expected to have risen 
48% between 2012 and 2030 (8). Despite improvements in con-
ventional treatments aimed at improving or re-establishing the 
revascularization of the infarcted myocardium (such as coronary 
artery bypass surgery or percutaneous coronary intervention), 
current therapies are limited (10, 11) and do not lead to regenera-
tion of the lost tissue. There is therefore an urgent need for novel 
therapies for the treatment of MI.
In this context, recent research has shown that whereas a 
regenerative response is limited in the adult mammalian heart, 
the adult zebrafish is able to regenerate lost or damaged cardiac 
tissue (12–15). Most importantly, additional studies have recently 
demonstrated that the neonatal mouse heart can fully regenerate 
after resection of the left ventricular (LV) apex, and after induc-
tion of MI at early stages (postnatal day 1, P1) (16–19). However, 
this regenerative capacity is only transient and is rapidly lost by 
7  days of age (18), indicating the existence of a “regenerative 
window” within the first week after birth in mice. Remarkably, 
newborn humans may also possess the intrinsic capacity to repair 
their heart after MI (19). Haubner et al. have recently observed 
full cardiac functional recovery within weeks after the occurrence 
of MI in a newborn child (19). While suggesting that the mam-
malian heart is able of regeneration, those findings also highlight 
the age-dependency of this process. This highlights the concept 
that the expression of distinct molecular switches activating or 
inhibiting cellular mechanisms regulating tissue regeneration 
vary during different stages of life. Thus, a better understand-
ing of the mechanisms that regulate complete cardiac repair 
and regeneration in the neonatal-infarcted heart could provide 
the basis for novel therapeutic approaches for cardiovascular 
regeneration following MI in the adult. This review illustrates the 
current understanding of the most important mechanisms that 
regulate cardiac regeneration in the neonatal mammalian heart 
and discusses the potential therapeutic targets that can be used 
in order to rejuvenate the adult-infarcted heart and improve its 
cardiac regeneration following MI.
CARDiAC ReGeneRATiOn: evOLUTiOn 
AnD DeveLOPMenT
Cardiac Regeneration in Lower 
vertebrates
Organ regeneration has been the focus of scientific research for 
over a century. For example, the ability of salamanders to regrow 
an entire lost limb after amputation has been studied for decades 
and their capacity to regenerate also other damaged parts of their 
bodies is still of interest in the field of regenerative medicine. 
Cardiac regeneration was however only recently investigated 
formally in lower vertebrate models. Zebrafish imposed itself as a 
standard model of cardiac regeneration as a result of its straight-
forward genetic manipulation and short generation time (20, 21).
Zebrafish (Danio rerio), a member of the teleost infraclass of 
bony fish, was first reported to harbor potent cardiac regenerative 
capacities by Poss et al. (12). After surgical removal of about 20% 
of the ventricular myocardium of adult fish, the authors initially 
observed a rapid formation of a blood clot. This was replaced by 
a fibrin cap by 9 days post-resection. Over the next 60 days, the 
fibrin cap was shown to regress as cardiomyocytes replaced the 
resected area, resulting in the complete regeneration of the myo-
cardium. Using this resection model, the authors were also able 
to show evidence of cardiomyocyte proliferation and suggested 
that cell proliferation was essential to scar-free regeneration of 
the adult zebrafish heart. Subsequently, other studies using line-
age tracing and electron microscopy techniques demonstrated 
that cardiomyocyte replenishment of the resected myocardium 
in the adult zebrafish occurred through existing cardiomyocyte 
de-differentiation and subsequent proliferation (15).
Cardiac Regeneration in Mammals
Mammalian models of cardiac regeneration were non-existent 
until the description by Porrello et al. that P1-old neonatal mice 
could fully regenerate their myocardium by 21  days follow-
ing apical resection (18). Subsequently, Porrello et  al. (17) and 
Haubner et al. (16) developed a model of MI in P1-old mice by 
ligation of the left coronary artery. Similarly to what observed 
with the resection model, neonatal mice could regenerate the 
injured myocardium by 21 days following MI at P1. This was also 
accompanied by full recovery of cardiac function. Importantly, 
this regenerative capacity is only transient and is strictly limited 
to the first week after birth. In fact, neonatal mice undergoing MI 
at P7 were unable to regenerate the lost myocardium and instead 
formed a scar, similar to the adult heart (17).
Myocardial infarction in P1 mice was associated with 
increased markers of cell death (such as cleaved caspase 3), 
functional decrease in the days following injury, and decreased 
proportion of viable myocardium (16, 17). At day 3 post-MI, 
observed extensive cardiomyocyte loss and immune cell infiltra-
tion were observed (17). By day 7, a scar had formed within the 
injured myocardium. This scar was then gradually removed as the 
myocardium regenerated leading to minimal interstitial fibrosis 
by day 21 post-MI. Similar to the zebrafish, neonatal mice were 
shown to achieve cardiac regeneration through de-differentiation 
and proliferation of cardiomyocytes, rather than through a stem-
cell-based mechanism (16–18).
It is commonly believed that following injury, developmental 
pathways such as Wnt, Notch, and Hedgehog are re-activated in 
an effort to restore tissue integrity (22, 23). It is however very 
clear that successful regeneration is both age-dependent and 
organ-specific (12, 17, 24). In this context, the existence of a 
“regenerative window” within the first week after birth (at least 
in mice) support the idea that the post-natal heart still harbors 
regenerative capacities that could be promoted after injury to 
improve the regenerative potential of the adult-infarcted heart 
and reduce the burden of MI.
The (Limited) Regenerative Capacity of the 
Human-infarcted Heart
Even though the adult mammalian heart clearly lacks potent 
regenerative capacities, a study by Bergmann et al. showed that 
the adult human heart was able of slow cardiomyocyte renewal 
throughout life (25). This suggests that the adult mammalian 
heart retains some regenerative capacities that may be stimulated 
to improve the outcome following MI.
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In contrast to the adult, newborn humans and infants seem 
to still harbor potent cardiac regenerative capacities. Indeed, 
a study by Fratz et  al. reported very little myocardial scarring 
and normal function in adults having had cardiac corrective 
surgery for anomalous origin of the left coronary artery from 
the pulmonary artery (ALPACA) as children (26). Moreover, in 
a recent case report Haubner et al. have recently observed full 
cardiac recovery within weeks after the occurrence of MI in a 
newborn child (19).
MeCHAniSMS OF CARDiAC 
ReGeneRATiOn AnD POTenTiAL 
THeRAPeUTiC TARGeTS
Achieving successful cardiac regeneration necessitate three key 
phenomena: cardiomyocyte replenishment, removal of interstitial 
fibrosis, and revascularization of the regenerated myocardium. 
Since the discovery of the neonatal mouse regenerative capacities, 
much work has focused on understanding the mechanisms behind 
it in the aim to identify targets to promote regeneration over scar 
formation in the adult myocardium following MI. Cardiomyocyte 
replenishment following neonatal MI is considered as the step 
limiting factor in achieving cardiac regeneration. To date, most of 
the research has therefore focused on the regulation of neonatal 
cardiomyocyte proliferation, and has identified several pathways 
and factors that are involved in the regulation of cardiomyocyte 
proliferation and that can be considered as potential therapeutic 
targets for improving cardiac regeneration in the adult-infarcted 
heart.
MicroRnAs (miRnAs)
Recent findings demonstrate that the regulation of cardiovascular 
development and regeneration is mediated by non-coding RNAs 
known as miRNAs (27–31). miRNAs are inhibitory regulators 
of gene expression, which act by binding to complementary 
mRNA transcripts for promoting either their degradation or 
translational repression (32). The expression of many miRNAs 
vary during different stages of life, reflecting their role as 
molecular switches that activate or inhibit cellular mechanisms 
that regulate cell and tissue development (33), including heart 
development (34).
In the neonatal mouse heart miRNAs have been linked to 
cardiomyocyte binucleation and cell cycle exit (35). miRNA 
expression profile performed in mouse cardiac ventricles isolated 
from P1 (within the regenerative window) and P10 (beyond the 
regenerative window) mice showed that 71 miRNAs are either up 
or downregulated during these developmental stages (35).
Notably, several large miRNA families (such as the miRNA-
15, miRNA-30, and let-7 families) were upregulated in P10 
cardiac ventricles, and miRNA-195 (a member of the miRNA-15 
family) was shown to be the most highly upregulated miRNA. 
Cardiomyocyte-targeted overexpression of miRNA-195 was 
associated with cardiac developmental defects and reduced 
cardiomyocyte proliferation in P1 mice (35). In addition, car-
diomyocyte-directed overexpression of miRNA-195 prevented 
cardiac regeneration of the neonatal mouse heart after induction 
of MI at P1. This was associated with decreased cardiomyocyte 
proliferation at day 7 post-MI, and impaired functional recovery 
and cardiomyocyte hypertrophy at day 21 post-MI (17).
Other miRNAs have been shown to regulate cardiomyocyte 
proliferation and regeneration. Eulalio et  al. (36) performed a 
high-throughput functional screening to assess the miRNAs 
capable of promoting cardiomyocytes proliferation. They found 
that at least 40 miRNAs increased both DNA synthesis and 
cytokinesis in neonatal mouse and rat cardiomyocytes. miRNA-
590 and miRNA-199 were further tested and showed to promote 
cell cycle re-entry of adult cardiomyocytes ex vivo. In addition, 
overexpression of either miRNA-199 or miRNA-590 in the heart 
of adult mice undergoing MI showed that both miRNAs induced 
cardiac regeneration and improved cardiac function (36).
Another study showed the involvement of the miRNA-17-92 
cluster in cardiomyocytes proliferation of postnatal and adult 
hearts (37). Nkx.2.5-mediated cardiac specific deletion of the 
miRNA-17-92 cluster resulted in partial embryonic lethality, and 
the miRNA-17-92 KO mice that survived had a smaller heart and 
a marked reduction of cardiomyocyte proliferation compared 
with littermate controls. On the other hand, cardiac specific 
conditional transgenic mice overexpressing the miRNA-17-92 
cluster were characterized by a significant increased proliferation 
of cardiomyocytes during either embryonic or postnatal stages. 
Moreover, these mice showed a higher heart/body weight ratio 
and increased thickness of the ventricular wall. Additionally, 
induction of MI in adult transgenic mice overexpressing the 
miRNA-17-92 cluster resulted in the reduction of the cardiac scar 
size, increased cardiomyocyte proliferation, and improvement of 
cardiac function (37).
The miRNA-34a has also been demonstrated to regulate 
cell-cycle activity and death in cardiomyocytes (38). miRNA-
34a expression in the heart is low in the early-postnatal period 
and it increases after P8 (beyond the regenerative window), and 
whereas overexpression of the miRNA-34a prevented cardiac 
regeneration in the neonatal mouse-infarcted heart, its inhibition 
improved cardiac function and repair in the adult-infarcted heart 
through the modulation of cell cycle and survival genes such as 
Bcl2, Cyclin D1, and Sirt1 (38).
The Hippo Signaling Pathway
The Hippo pathway has been demonstrated to be critically 
involved in cardiac development and regeneration and may 
represent a promising therapeutic target in the setting of MI. The 
pathway consists of a cascade of kinases controlling cell prolifera-
tion and organ size. Activation of the Hippo pathway leads to the 
phosphorylation of the transcriptional co-activators yes associ-
ated protein (YAP) and WW domain-containing transcription 
regulator protein 1 (TAZ). This prevents their nuclear localization 
and, in the fetal mouse heart, restrains cardiomyocyte prolifera-
tion (39, 40). Inactivation of the pathway indeed leads to largely 
overgrown hearts with increased cardiomyocyte proliferation 
(40). Conversely, cardiac specific deletion of YAP is associated 
with decreased cardiomyocyte proliferation at P1 and the devel-
opment of dilated cardiomyopathy in adults.
The Hippo/YAP axis also plays crucial roles following cardiac 
injury in both neonatal and adult mice. Cardiac specific deletion 
4
Castellan  and Meloni Cardiac Regeneration and Age Gap
Frontiers in Cardiovascular Medicine | www.frontiersin.org February 2018 | Volume 5 | Article 7
of YAP abrogates the regenerative response of neonatal mice lead-
ing to the formation a fibrotic scar and functional impairment by 
day 27 post-MI. On the other hand, stabilization of YAP promotes 
proliferation of cardiomyocytes following injury in mice at P28, 
thus outside of the regenerative window, suggesting potential for 
the pathway to be manipulated to unlock cardiac regenerative 
capacities in the adult mammal. The Hippo pathway therefore 
represents a key modulator of cardiac regeneration and more 
specifically cardiomyocyte replenishment.
Due to the emerging role of the pathway in controlling organ 
growth and size as well as its tumor suppressor capacities, phar-
macological manipulation of the pathway has been the focus of a 
number of studies (41). Of interest, the small molecule inhibitor 
9E1 has shown promising in vitro results in targeting mammalian 
STE20-like protein kinases (MSTs); kinases involved in the phos-
phorylation and thereby repression of YAP/TAZ. The use of such 
inhibitor in vivo is yet to be tested but may represent an avenue for 
the manipulation of the Hippo pathway with the aim to unlock 
cardiac regenerative capacities in the adult mammalian heart. 
Recently, deletion of the Hippo pathway component Salvador 
has been shown to increase vascularity and reduce fibrosis in 
the mouse-infarcted heart, leading to improved cardiac function 
(42). Moreover, gene therapy-mediated knockdown of Salvador 
in cardiomyocytes induced their proliferation improving cardiac 
function after MI, thus confirming the Hippo pathway as poten-
tial therapeutic target after MI.
Meis1
Meis1 belongs to the TALE family of homeodomain transcription 
factor and is well known for its role in hematopoiesis (43). Meis1 
has been also shown to be essential for cardiac development (44, 
45) and has recently been identified as being critical for postnatal 
cardiomyocyte proliferation (46). Cardiomyocyte-specific dele-
tion of Meis1 resulted in increased cardiomyocyte proliferation 
and increased percentage of mononucleated cardiomyocytes 
postnatally (P14, beyond the regenerative window). On the other 
hand, induction of MI in P1-old cardiac-specific Meis1 overex-
pressing mice resulted in premature cell-cycle arrest and inhibi-
tion of cardiac regeneration, thus suggesting a role for Meis1 in 
cell-cycle activity and cardiomyocytes nucleation. Interestingly, 
miRNA-548c-3p, miRNA-509-3p, and miRNA23b-3p were 
shown to induce significant proliferation of adult rat cardiomyo-
cytes through translational inhibition of Meis1 (47). Moreover, 
it was also recently shown that Tbx20 (a member of the Tbx1 
subfamily of T-box genes which is required for cardiomyocyte 
proliferation during heart development) (48) can act as tran-
scriptional repressor of Mes1 leading to increased proliferation 
of cardiomyocytes and preservation of cardiac function following 
MI in adult mice (49), thus confirming the key role of Meis1 in 
regulating cardiomyocyte proliferation and its promising poten-
tial as therapeutic target for cardiac regeneration post-MI.
immune Response Signals
The immune system is actively involved in tissue growth during 
development and participates to tissue repair and regeneration 
after injury (including MI) (50–53). Following MI, necrotic 
cell death triggers an immune response characterized by the 
activation of inflammatory cells (mainly monocytes/mac-
rophages) responsible for removing dead cells and debris, and for 
secreting cytokines and factors in order to attempt to restore the 
integrity of the injured heart (50–54). In the adult-infarcted heart 
this immune response participates in the activation of fibroblasts 
and proliferation of endothelial cells (55, 56). This leads to the 
formation of a fibrotic scar, thus preventing the rupture of the 
ventricular wall but contributing to a progressive impairment of 
cardiac function which eventually leads to HF (57).
On the other hand, macrophages are required for scar-free 
regeneration of the neonatal mouse heart following MI (53, 58). 
Interestingly, neonatal mice mobilize a subset of tissue-resident 
macrophages of yolk-sac origin immediately following genetic 
ablation of cardiomyocytes, whereas adult mice preferentially 
expand a population of bone-marrow-derived macrophages (59). 
Cardiac yolk-sac-derived macrophages have increased angiogenic 
capacities in vitro as compared with adult bone-marrow-derived 
macrophages (59). Such differences in the immune response and 
the intrinsic capacities of the cells involved may therefore par-
ticipate in the regenerative capacities of the neonatal mouse (60). 
Recently, Quaife-Ryan et al. (61) published an extensive report 
on the transcriptional differences between neonatal and adult 
leukocytes following MI which may contribute to a regenerative 
or fibrotic phenotype. This study sets a stepping stone to in-depth 
characterization of the pathways involved during regeneration vs. 
fibrotic repair. Further studies should investigate the roles and 
interplay of the different leukocyte population during regenera-
tion and fibrotic repair in order to identify targets for the promo-
tion of regeneration. More information about the importance of 
immune modulation if cardiac repair and regeneration can be 
found in Zlatanova et al. (58).
Cardiac-Resident Stem/Progenitor Cells
The adult mouse heart possesses a resident population of c-kit+/
Lin− cells expressing markers of cardiomyocyte progenitors with 
clonogenic, self-renewing capacities and able to differentiate into 
several cell types including cardiomyocytes (62), and the c-kit+ 
cell population has been shown to act as cardiomyocyte progeni-
tors in the adult mouse following injury (63). Interestingly, also 
the human heart contains a population of c-kit+ cardiac-resident 
stem cells that can divide and differentiate into myocytes (64), but 
their regenerative potential decreases in the setting of chronic HF 
and is associated with decreased telomerase activity and cellular 
senescence (64). However, c-kit is expressed by a heterogeneous 
population (65, 66) and only a very small fraction of c-kit+ cells 
has the ability to differentiate into cardiomyocytes (66). In this 
context, however, although regeneration of the neonatal heart has 
been proposed to occur through de-differentiation of cardiomyo-
cytes, the role (if any) of resident cardiac stem/progenitor cells in 
the neonatal heart regeneration has not been investigated.
COnCLUSiOn
The regeneration potential of essentially all tissues and organs, 
including the heart, is known to decrease during the aging process. 
The observation that the neonatal mouse heart possesses potent 
regenerative capacities has provided the field of cardiovascular 
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regeneration with a strong model for the identification of path-
ways and therapeutic targets for the promotion of regeneration 
over fibrotic repair following MI. As outlined in this review, a 
number of pathways and factors that regulate cardiovascular 
regeneration of the neonatal heart have been identified. These 
pathways represent potential therapeutic targets for rejuvenation 
of aging hearts and for improving regeneration of the adult-
infarcted heart.
AUTHOR COnTRiBUTiOnS
RC and MM performed literature search and wrote the manuscript.
FUnDinG
This work was supported by the British Heart Foundation UK 
Cardiovascular Regenerative Medicine Centre (to MM).
ReFeRenCeS
1. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart 
disease: mechanisms and significance. Annu Rev Physiol (2010) 72:19–44. 
doi:10.1146/annurev.physiol.010908.163111 
2. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication 
of diabetes. Diabetes Care (2003) 26:2433–41. doi:10.2337/diacare.26.8.2433 
3. Park M, Shen YT, Gaussin V, Heyndrickx GR, Bartunek J, Resuello RR, et al. 
Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart 
Circ Physiol (2009) 297:H785–91. doi:10.1152/ajpheart.00310.2009 
4. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a 
role for interstitial fibrosis. Mol Cell Biochem (1995) 147:29–34. doi:10.1007/
BF00944780 
5. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. 
Declining in-hospital mortality and increasing heart failure incidence in 
elderly patients with first myocardial infarction. J Am Coll Cardiol (2009) 
53:13–20. doi:10.1016/j.jacc.2008.08.067 
6. Behfar A, Terzic A, Perez-Terzic CM. Regenerative principles enrich cardiac 
rehabilitation practice. Am J Phys Med Rehabil (2014) 93:S169–75. doi:10.1097/
PHM.0000000000000147 
7. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart 
disease and stroke statistics – 2007 update: a report from the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 
(2007) 115:e69–171. doi:10.1161/CIRCULATIONAHA.106.179918 
8. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. 
American Heart Association Statistics C and Stroke Statistics S. Heart Disease and 
Stroke Statistics-2016 update: a Report from the American Heart Association. 
Circulation (2016) 133:e38–360. doi:10.1161/CIR.0000000000000350 
9. Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of 
heart failure in older adults. Heart Fail Clin (2017) 13:417–26. doi:10.1016/j.
hfc.2017.02.001 
10. Task Force on Myocardial Revascularization of the European Society of 
Cardiology (ESC) and the European Association for Cardio-Thoracic 
Surgery (EACTS); European Association for Percutaneous Cardiovascular 
Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, et  al. 
Guidelines on myocardial revascularization. Eur Heart J (2010) 31:2501–55. 
doi:10.1093/eurheartj/ehq277 
11. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for 
patients? Stem cell therapy for cardiac repair. Ready for the next step. Circulation 
(2006) 114:339–52. doi:10.1161/CIRCULATIONAHA.105.590653 
12. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science 
(2002) 298:2188–90. doi:10.1126/science.1077857 
13. Forbes SJ, Rosenthal N. Preparing the ground for tissue regeneration: from 
mechanism to therapy. Nat Med (2014) 20:857–69. doi:10.1038/nm.3653 
14. Major RJ, Poss KD. Zebrafish heart regeneration as a model for cardiac 
tissue repair. Drug Discov Today Dis Models (2007) 4:219–25. doi:10.1016/j.
ddmod.2007.09.002 
15. Jopling C, Sleep E, Raya M, Marti M, Raya A, Izpisua Belmonte JC. Zebrafish 
heart regeneration occurs by cardiomyocyte dedifferentiation and prolifera-
tion. Nature (2010) 464:606–9. doi:10.1038/nature08899 
16. Haubner BJ, Adamowicz-Brice M, Khadayate S, Tiefenthaler V, Metzler B, 
Aitman T, et al. Complete cardiac regeneration in a mouse model of myocar-
dial infarction. Aging (2012) 4:966–77. doi:10.18632/aging.100526 
17. Porrello ER, Mahmoud AI, Simpson E, Johnson BA, Grinsfelder D, Canseco D, 
et al. Regulation of neonatal and adult mammalian heart regeneration by the 
miR-15 family. Proc Natl Acad Sci U S A (2013) 110:187–92. doi:10.1073/pnas. 
1208863110 
18. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, 
et  al. Transient regenerative potential of the neonatal mouse heart. Science 
(2011) 331:1078–80. doi:10.1126/science.1200708 
19. Haubner BJ, Schneider J, Schweigmann U, Schuetz T, Dichtl W, Velik-Salchner C, 
et al. Functional recovery of a human neonatal heart after severe myocardial 
infarction. Circ Res (2016) 118:216–21. doi:10.1161/CIRCRESAHA.115.307017 
20. Rumyantsev PP. Autoradiographic study on the synthesis of DNA, RNA, and 
proteins in normal cardiac muscle cells and those changed by experimental 
injury. Folia Histochem Cytochem (1966) 4:397–424. 
21. Oberpriller JO, Oberpriller JC. Response of the adult newt ventricle to injury. 
J Exp Zool (1974) 187:249–53. doi:10.1002/jez.1401870208 
22. Bielefeld KA, Amini-Nik S, Alman BA. Cutaneous wound healing: recruiting 
developmental pathways for regeneration. Cell Mol Life Sci (2013) 70:2059–81. 
doi:10.1007/s00018-012-1152-9 
23. Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the 
heart of regeneration. J Mol Cell Cardiol (2011) 50:296–303. doi:10.1016/j.
yjmcc.2010.07.006 
24. Porrello ER, Olson EN. A neonatal blueprint for cardiac regeneration. Stem 
Cell Res (2014) 13(3 Pt B):556–70. doi:10.1016/j.scr.2014.06.003 
25. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, 
et  al. Evidence for cardiomyocyte renewal in humans. Science (2009) 
324:98–102. doi:10.1126/science.1164680 
26. Fratz S, Hager A, Schreiber C, Schwaiger M, Hess J, Stern HC. Long-term 
myocardial scarring after operation for anomalous left coronary artery from 
the pulmonary artery. Ann Thorac Surg (2011) 92:1761–5. doi:10.1016/j.
athoracsur.2011.06.021 
27. Porrello ER. MicroRNAs in cardiac development and regeneration. Clin Sci 
(Lond) (2013) 125:151–66. doi:10.1042/CS20130011 
28. Caporali A, Emanueli C. MicroRNA regulation in angiogenesis. Vascul 
Pharmacol (2011) 55:79–86. doi:10.1016/j.vph.2011.06.006 
29. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent 
microRNAs regulate gene expression and functions in human endothelial 
cells. Circ Res (2007) 100:1164–73. doi:10.1161/01.RES.0000265065.26744.17 
30. Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, 
et  al. Dicer-dependent endothelial microRNAs are necessary for postnatal 
angiogen esis. Proc Natl Acad Sci U S A (2008) 105:14082–7. doi:10.1073/
pnas.0804597105 
31. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha 
for endothelial microRNA expression and angiogenesis. Circ Res (2007) 
101:59–68. doi:10.1161/CIRCRESAHA.107.153916 
32. Asli NS, Pitulescu ME, Kessel M. MicroRNAs in organogenesis and disease. 
Curr Mol Med (2008) 8:698–710. doi:10.2174/156652408786733739 
33. Williams AH, Liu N, van Rooij E, Olson EN. MicroRNA control of muscle 
development and disease. Curr Opin Cell Biol (2009) 21:461–9. doi:10.1016/j.
ceb.2009.01.029 
34. Espinoza-Lewis RA, Wang DZ. MicroRNAs in heart development. Curr Top 
Dev Biol (2012) 100:279–317. doi:10.1016/B978-0-12-387786-4.00009-9 
35. Porrello ER, Johnson BA, Aurora AB, Simpson E, Nam YJ, Matkovich SJ, et al. 
miR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res 
(2011) 109:670–9. doi:10.1161/CIRCRESAHA.111.248880 
36. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, et al. 
Functional screening identifies miRNAs inducing cardiac regeneration. 
Nature (2012) 492:376–81. doi:10.1038/nature11739 
37. Chen J, Huang ZP, Seok HY, Ding J, Kataoka M, Zhang Z, et al. mir-17-92 
cluster is required for and sufficient to induce cardiomyocyte proliferation 
in postnatal and adult hearts. Circ Res (2013) 112:1557–66. doi:10.1161/
CIRCRESAHA.112.300658 
6
Castellan  and Meloni Cardiac Regeneration and Age Gap
Frontiers in Cardiovascular Medicine | www.frontiersin.org February 2018 | Volume 5 | Article 7
38. Yang Y, Cheng HW, Qiu Y, Dupee D, Noonan M, Lin YD, et al. MicroRNA-
34a plays a key role in cardiac repair and regeneration following myocardial 
infarction. Circ Res (2015) 117:450–9. doi:10.1161/CIRCRESAHA.117.305962 
39. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 
(2010) 19:491–505. doi:10.1016/j.devcel.2010.09.011 
40. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, et al. 
Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation 
and heart size. Science (2011) 332:458–61. doi:10.1126/science.1199010 
41. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway 
for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2014) 
13:63–79. doi:10.1038/nrd4161 
42. Leach JP, Heallen T, Zhang M, Rahmani M, Morikawa Y, Hill MC, et al. Hippo 
pathway deficiency reverses systolic heart failure after infarction. Nature 
(2017) 550:260–4. doi:10.1038/nature24045 
43. Argiropoulos B, Yung E, Humphries RK. Unraveling the crucial roles of Meis1 
in leukemogenesis and normal hematopoiesis. Genes Dev (2007) 21:2845–9. 
doi:10.1101/gad.1619407 
44. Paige SL, Thomas S, Stoick-Cooper CL, Wang H, Maves L, Sandstrom R, et al. 
A temporal chromatin signature in human embryonic stem cells identifies 
regulators of cardiac development. Cell (2012) 151:221–32. doi:10.1016/j.
cell.2012.08.027 
45. Wamstad JA, Alexander JM, Truty RM, Shrikumar A, Li F, Eilertson KE, et al. 
Dynamic and coordinated epigenetic regulation of developmental transitions 
in the cardiac lineage. Cell (2012) 151:206–20. doi:10.1016/j.cell.2012.07.035 
46. Mahmoud AI, Kocabas F, Muralidhar SA, Kimura W, Koura AS, Thet S, et al. 
Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature (2013) 
497:249–53. doi:10.1038/nature12054 
47. Pandey R, Yang Y, Jackson L, Ahmed RP. MicroRNAs regulating meis1 expres-
sion and inducing cardiomyocyte proliferation. Cardiovasc Regen Med (2016) 
3:e1468. doi:10.14800/crm.1468
48. Greulich F, Rudat C, Kispert A. Mechanisms of T-box gene function in the 
developing heart. Cardiovasc Res (2011) 91:212–22. doi:10.1093/cvr/cvr112 
49. Xiang FL, Guo M, Yutzey KE. Overexpression of Tbx20 in adult cardiomyocytes 
promotes proliferation and improves cardiac function after myocardial infarc-
tion. Circulation (2016) 133:1081–92. doi:10.1161/CIRCULATIONAHA. 
115.019357 
50. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et  al. 
Targeted disruption of the mouse colony-stimulating factor 1 receptor 
gene results in osteopetrosis, mononuclear phagocyte deficiency, increased 
primitive progenitor cell frequencies, and reproductive defects. Blood (2002) 
99:111–20. doi:10.1182/blood.V99.1.111 
51. Pollard JW. Trophic macrophages in development and disease. Nat Rev 
Immunol (2009) 9:259–70. doi:10.1038/nri2528 
52. Frangogiannis NG. The inflammatory response in myocardial injury, 
repair, and remodelling. Nat Rev Cardiol (2014) 11(5):255–65. doi:10.1038/
nrcardio.2014.28
53. Aurora AB, Porrello ER, Tan W, Mahmoud AI, Hill JA, Bassel-Duby R, et al. 
Macrophages are required for neonatal heart regeneration. J Clin Invest (2014) 
124:1382–92. doi:10.1172/JCI72181 
54. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. 
Circ Res (2012) 110:159–73. doi:10.1161/CIRCRESAHA.111.243162 
55. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, 
et al. The healing myocardium sequentially mobilizes two monocyte subsets 
with divergent and complementary functions. J Exp Med (2007) 204:3037–47. 
doi:10.1084/jem.20070885 
56. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macro-
phage polarization. J Leukoc Biol (2011) 89:557–63. doi:10.1189/jlb.0710409 
57. Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from 
repair and remodeling to regeneration. Cell Tissue Res (2016) 365:563–81. 
doi:10.1007/s00441-016-2431-9 
58. Zlatanova I, Pinto C, Silvestre JS. Immune modulation of cardiac repair and 
regeneration: the art of mending broken hearts. Front Cardiovasc Med (2016) 
3:40. doi:10.3389/fcvm.2016.00040 
59. Lavine KJ, Epelman S, Uchida K, Weber KJ, Nichols CG, Schilling JD, et al. 
Distinct macrophage lineages contribute to disparate patterns of cardiac 
recovery and remodeling in the neonatal and adult heart. Proc Natl Acad Sci 
U S A (2014) 111:16029–34. doi:10.1073/pnas.1406508111 
60. Sattler S, Rosenthal N. The neonate versus adult mammalian immune system 
in cardiac repair and regeneration. Biochim Biophys Acta (2016) 1863:1813–21. 
doi:10.1016/j.bbamcr.2016.01.011 
61. Quaife-Ryan GA, Sim CB, Ziemann M, Kaspi A, Rafehi H, Ramialison M, 
et al. Multi-cellular transcriptional analysis of mammalian heart regeneration. 
Circulation (2017) 136(12):1123–39. doi:10.1161/CIRCULATIONAHA.117. 
028252 
62. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. 
Adult cardiac stem cells are multipotent and support myocardial regeneration. 
Cell (2003) 114:763–76. doi:10.1016/S0092-8674(03)00687-1 
63. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, et al. Adult 
c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac 
regeneration and repair. Cell (2013) 154:827–42. doi:10.1016/j.cell.2013.07.039 
64. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri F, 
et  al. Myocardial regeneration by activation of multipotent cardiac stem 
cells in ischemic heart failure. Proc Natl Acad Sci U S A (2005) 102:8692–7. 
doi:10.1073/pnas.0500169102 
65. Santini MP, Forte E, Harvey RP, Kovacic JC. Developmental origin and lineage 
plasticity of endogenous cardiac stem cells. Development (2016) 143:1242–58. 
doi:10.1242/dev.111591 
66. Vicinanza C, Aquila I, Scalise M, Cristiano F, Marino F, Cianflone E, et al. 
Adult cardiac stem cells are multipotent and robustly myogenic: c-kit expres-
sion is necessary but not sufficient for their identification. Cell Death Differ 
(2017) 24:2101–16. doi:10.1038/cdd.2017.130 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Castellan and Meloni. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) and the copyright owner are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, distribu-
tion or reproduction is permitted which does not comply with these terms.
